Recently it was proposed that impaired glymphatic clearance of toxic metabolites is a common mechanism for dementia diseases, such as Alzheimer's disease (amyloid-β, tau), and Parkinson's disease (α-synuclein) (25). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.